Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itolizumab in Subjects Hospitalized With COVID-19
NCT04605926Phase 3Withdrawn
- Sponsor
- Biocon
- Start
- Nov 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing EQ001 with EQ001 Placebo (2 arms). Primary endpoint: Proportion of subjects who have recovered at Day 28. Planned start Nov 2020; status: withdrawn.
02
Drugs
itolizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04605926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605926.